189 related articles for article (PubMed ID: 19953652)
1. Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.
Sally EJ; Xu H; Dersch CM; Hsin LW; Chang LT; Prisinzano TE; Simpson DS; Giuvelis D; Rice KC; Jacobson AE; Cheng K; Bilsky EJ; Rothman RB
Synapse; 2010 Apr; 64(4):280-8. PubMed ID: 19953652
[TBL] [Abstract][Full Text] [Related]
2. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence.
Xu H; Partilla JS; Wang X; Rutherford JM; Tidgewell K; Prisinzano TE; Bohn LM; Rothman RB
Synapse; 2007 Mar; 61(3):166-75. PubMed ID: 17152090
[TBL] [Abstract][Full Text] [Related]
3. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
4. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
Wang D; Raehal KM; Bilsky EJ; Sadée W
J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242
[TBL] [Abstract][Full Text] [Related]
5. Salvinorin A: allosteric interactions at the mu-opioid receptor.
Rothman RB; Murphy DL; Xu H; Godin JA; Dersch CM; Partilla JS; Tidgewell K; Schmidt M; Prisinzano TE
J Pharmacol Exp Ther; 2007 Feb; 320(2):801-10. PubMed ID: 17060492
[TBL] [Abstract][Full Text] [Related]
6. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Wang D; Sun X; Sadee W
J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
[TBL] [Abstract][Full Text] [Related]
7. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors.
Xu H; Wang X; Partilla JS; Bishop-Mathis K; Benaderet TS; Dersch CM; Simpson DS; Prisinzano TE; Rothman RB
Brain Res Bull; 2008 Sep; 77(1):49-54. PubMed ID: 18639745
[TBL] [Abstract][Full Text] [Related]
9. Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity.
Iyer MR; Lee YS; Deschamps JR; Dersch CM; Rothman RB; Jacobson AE; Rice KC
Eur J Med Chem; 2012 Apr; 50():44-54. PubMed ID: 22341895
[TBL] [Abstract][Full Text] [Related]
10. Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening.
Brillet K; Kieffer BL; Massotte D
BMC Pharmacol; 2003 Dec; 3():14. PubMed ID: 14641935
[TBL] [Abstract][Full Text] [Related]
11. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
12. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
Wang D; Raehal KM; Lin ET; Lowery JJ; Kieffer BL; Bilsky EJ; Sadée W
J Pharmacol Exp Ther; 2004 Feb; 308(2):512-20. PubMed ID: 14600246
[TBL] [Abstract][Full Text] [Related]
13. Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.
Divin MF; Bradbury FA; Carroll FI; Traynor JR
Br J Pharmacol; 2009 Apr; 156(7):1044-53. PubMed ID: 19220294
[TBL] [Abstract][Full Text] [Related]
14. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
Olianas MC; Concas D; Onali P
Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
[TBL] [Abstract][Full Text] [Related]
15. Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.
Purington LC; Sobczyk-Kojiro K; Pogozheva ID; Traynor JR; Mosberg HI
ACS Chem Biol; 2011 Dec; 6(12):1375-81. PubMed ID: 21958158
[TBL] [Abstract][Full Text] [Related]
16. Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management.
Sadee W; Oberdick J; Wang Z
Molecules; 2020 Sep; 25(18):. PubMed ID: 32932935
[TBL] [Abstract][Full Text] [Related]
17. Development of displacement binding and GTPgammaS scintillation proximity assays for the identification of antagonists of the micro-opioid receptor.
Rodgers G; Hubert C; McKinzie J; Suter T; Statnick M; Emmerson P; Stancato L
Assay Drug Dev Technol; 2003 Oct; 1(5):627-36. PubMed ID: 15090235
[TBL] [Abstract][Full Text] [Related]
18. CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells.
Cinar R; Szücs M
J Pharmacol Exp Ther; 2009 Aug; 330(2):567-74. PubMed ID: 19448142
[TBL] [Abstract][Full Text] [Related]
19. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
Liu JG; Prather PL
J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
[TBL] [Abstract][Full Text] [Related]
20. Anti-mu opioid antiserum against the third external loop of the cloned mu-opioid receptor acts as a mu receptor neutral antagonist.
Guarna M; Bartolini A; Ghelardini C; Galeotti N; Bracci L; Stefano GB; Bianchi E
Brain Res Mol Brain Res; 2003 Nov; 119(1):100-10. PubMed ID: 14597234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
